Shennuo Medical Secures Hundreds of Millions in Series B+ Funding as Multiple Key Neuromodulation Products Enter Clinical Registration Phase

VCBeat learned第一时间 that recently,SNEURO MEDICAL (hereinafter referred to as "SNEURO MEDICAL")Announced the completion of a Series B+ financing round worth hundreds of millions of yuan.This round of financing was led by OrbiMed, with follow-up investment from existing shareholder BioTrack Capital.This round of financing will be mainly used for SNEURO MEDICAL'sNew product development, clinical research, registration application, core technology iteration, and commercial expansion.

As a neuromodulation platform company, SNEURO MEDICAL is committed to the independent research, development, and production of medical devices in the fields of implantable neural stimulation and brain-computer interfaces, with the goal of continuously providing affordable neuromodulation treatment products for patients. The company's core team has more than ten years of experience in the research and production of complete sets of implantable devices, as well as strong capabilities in product development, system building, and commercial expansion. Since its registration and establishment in December 2018, the company has applied for more than 100 related patents and software copyrights.With three major technological platforms—short-term implantation, rechargeable IPG, and wireless power transmission—it has mastered key core technologies such as electrodes, chips, wireless charging, and algorithms, possessing the core capability to continuously introduce new products and technologies in the field of neuromodulation.

Currently, for different diseases,The company has successfully developed multiple implantable neurostimulators. Some products have completed clinical enrollment, and some products are about to initiate clinical trials.In the future, SNEURO MEDICAL will continue to launch its self-developed products into the market for conditions such as pain, overactive bladder, sleep apnea syndrome, hypertension, and heart failure, building a neuromodulation solution platform to benefit more patients.

SNEURO MEDICAL founder Wang Shou Dong stated"Thanks to the strong support from both new and existing shareholders, there is still much unknown in the field of neuromodulation, which is worth the company's deep exploration. An increasing number of indications have been proven to have clear efficacy. SNEURO MEDICAL will continue to focus on the research and development of neuromodulation, aiming to make neuromodulation accessible to everyone. Through continuous independent innovation, the company will develop more effective products, providing patients with increasingly effective treatment options."

OrbiMed Partner Dr. David Wang stated"SNEURO MEDICAL possesses leading technological strength and platforms not only in China but also globally. Several of the company's key products have entered the late clinical stage or the late product development stage, with outstanding trial data. We are honored to collaborate with SNEURO MEDICAL to bring multiple more effective and accessible neuromodulation treatment products to patients in China and around the world, targeting various disease areas. We look forward to accompanying the company on its journey to become a global leader in neuromodulation."

BioTrack Capital Executive Director Anan Wu stated"As an existing shareholder, we have invested in SNEURO MEDICAL multiple times. In today’s highly challenging financing environment, we are honored to stand alongside outstanding and promising medical startups like SNEURO MEDICAL. Neuromodulation represents a vast market with new indications and technological pathways continually emerging, marking it as a track capable of sustained growth. We will also actively support the company in its development into a new generation of representative China-produced medical device enterprises."

OrbiMed, founded in 1989, is the world's largest investment firm focused on the biomedicine sector, committed to identifying and supporting biomedicine and life science companies that can promote human health. Since its establishment, OrbiMed has set up a series of private equity funds and debt/credit funds globally, with investment targets covering everything from startups to large multinational corporations. Investment projects span across fields such as biopharmaceuticals, life sciences, medical devices, healthcare services, and diagnostics. The investments focus primarily on immunotherapy, gene therapy, and gene editing.

BioTrack Capital was founded in 2017 as a professional investment institution focused on investing in and incubating outstanding healthcare startups in the Chinese market. We are not only investors, but also long-term partners of entrepreneurs. We consistently support the most exceptional healthcare innovators in building the next generation of leading enterprises in China’s healthcare industry.